No Data
Jianmin Pharmaceutical Group (600976.SH): A subsidiary plans to invest 12.31 million yuan to renovate the pre-processing building.
On December 17, Gelonghui reported that Jianmin Pharmaceutical Group (600976.SH) announced that the Board of Directors approved its wholly-owned subsidiary Jianmin Pharmaceutical Group Yekai Thailand Co., Ltd. to invest 12.31 million yuan from its own funds to renovate the preprocessing building.
Jianmin Pharmaceutical Group (600976.SH): A controlled subsidiary plans to invest 5 million yuan to open a new traditional Chinese medicine clinic in the Optics Valley area.
Gelonghui, December 17th丨Jianmin Pharmaceutical Group (600976.SH) announced that the Board of Directors approved its holding subsidiary Jianmin Yekai Thai Medical Investment (Hubei) Co., Ltd. to invest 5 million yuan from its own funds to open a new traditional Chinese medicine clinic in the Optics Valley area.
Cautious Investors Not Rewarding Jianmin Pharmaceutical Group Co.,Ltd.'s (SHSE:600976) Performance Completely
jianmin pharmaceutical group (600976.SH): the company's new product entries and renewed listings in the national medical insurance catalog.
On November 28, Gelonghui reported that jianmin pharmaceutical group (600976.SH) announced that the National Healthcare Security Administration and the Ministry of Human Resources and Social Security released a notice regarding the publication of the "National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Pharmaceutical Catalogue (2024)." According to this notice, the company's product, Pediatric Zibei Xuanfei Syrup, has been included in the "National Basic Medical Insurance Catalogue (2024)" for the first time through negotiation, and Qirui Weishu Capsules will continue to be included in the "National Medical Insurance Catalogue (2024)" under the negotiation renewal period.
Is Jianmin Pharmaceutical GroupLtd (SHSE:600976) A Risky Investment?
China Great Wall Securities: Research and development of substitute products for rare traditional Chinese medicine is supported, and the launch of new products is expected to accelerate.
On October 21, the National Medical Products Administration and the State Administration of Traditional Chinese Medicine jointly issued the "Notice on Supporting the Research and Development of Substitute for Endangered Rare Traditional Chinese Medicine Materials", proposing specific measures such as strengthening collaboration between industry, academia, and research, enhancing technical guidance, and accelerating review and approval.
Jianmin Pharmaceutical GroupLtd's (SHSE:600976) Solid Profits Have Weak Fundamentals
No Data
